Novo Integrated Sciences, Inc.

As of November 6, 2024, Novo Integrated Sciences, Inc. is deemed overvalued and classified as "does not qualify" due to poor financial health, reflected in its negative valuation metrics and a year-to-date return of -99.04%, significantly underperforming compared to the S&P 500's 12.22% gain.

As of April 1, 2025, the trend is mildly bearish due to daily moving averages, despite some bullish signals from weekly and monthly MACD readings, while the RSI indicates a lack of momentum.

Novo Integrated Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net profit of $5 million as of August 2024. The company has a market cap of $0.07 million and shows a return on equity of -120.60%.

As of Jun 18, Novo Integrated Sciences, Inc. has a market capitalization of 0.07 million, categorizing it as a Micro Cap company, with net sales of 13.29 million and a net profit of -16.14 million over the latest four quarters. As of August 2024, the company's shareholder's funds were 14.89 million, and total assets were 32.14 million.